201669-69-4

Upstream product

• 1774-47-6 trimethylsulfoxonium iodide 
• 201669-68-3 (E)-1-((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-3-(1-trityl-1H-imidazol-4-yl)-propenone 
• 94594-90-8 (2R)-bornane-10,2-sultam 
• 76-83-5 trityl chloride 
• 25274-93-5 sec-butyl (2E)-3-(1H-imidazol-4-yl)acrylate 
• 3465-72-3 urocanic Acid 
• 25274-94-6 sec-butyl (2E)-3-(1-trityl-1H-imidazol-4-yl)acrylate 
• 25206-11-5 sec-butyl 2-(1-trityl-1H-imidazol-4-yl)cyclopropanecarboxylate 
• 201669-67-2 (E)-1-((1S,5R,7R)-10,10-Dimethyl-3,3-dioxo-3λ⁶-thia-4-aza-tricyclo[5.2.1.0^1,5]dec-4-yl)-3-(1H-imidazol-4-yl)-propenone 

Downstream Products

• 201669-71-8 (1S,2S)-1-(1-triphenylmethyl-1H-imidazol-4-yl)cyclopropane-2-carboxylic acid 
• 408348-69-6 (1S,2S)-2-formyl-1-(1-triphenylmethyl-1H-imidazol-4-yl)cyclopropane 
• 223419-93-0 (1S,2S)-4-(2-ethynylcyclopropyl)-1-(triphenylmethyl)imidazole 
• 223419-90-7 4-((1S,2S)-2-(5,5-dimethyl-hex-1-yn-1-yl)-cyclopropyl)-1-trityl-1H-imidazole 

Relevant academic research and scientific papers

An Efficient Multigram Synthesis of the Potent Histamine H3 Antagonist GT-2331 and the Reassessment of the Absolute Configuration

GT-2331 is a potent histamine H3 antagonist which has entered clinical trials. Efficient multigram syntheses of this compound and its enantiomer are described. The literature reports that GT-2331 is the dextrorotatory (+), more potent, enantiom

Diastereoselective synthesis of trans-2-(1-triphenylmethyl-1H-imidazol-4-yl)cyclopropanecarboxylic acids: Key intermediates for the preparation of potent and chiral histamine H3 receptor agents

Procedures for the preparation of both enantiomers of trans-2-(1-triphenylmethyl-1H-imidazol-4-yl)-cyclopropanecarboxylic acid are described. The key step in the synthesis is a 3:1 diastereoselective cyclopropanation of (5R)-trans-4-aza-10,10-dimethyl-3-t